The Tumor Microenvironment of High Grade Serous Ovarian Cancer

Guest Editors:

**Prof. Dr. M. Sharon Stack**
Sharon.Stack.11@nd.edu

**Prof. Dr. Kenneth P Nephew**
k nephew@indiana.edu

**Dr. Joanna E. Burdette**
joannab@uic.edu

**Dr. Anirban K. Mitra**
anmitra@indiana.edu

Deadline for manuscript submissions:
closed (1 June 2018)

**Message from the Guest Editors**

This Special Issue focuses on high grade serous ovarian cancer (HGSOC) and the contribution of the tumor microenvironment (TME) to the unique features of this most lethal of the gynecologic malignancies and one of the most lethal of the peritoneal cancers. As HGSOC metastases have a highly complex TME, there is an urgent need to better understand the TME in general, its distinct components in particular, and the role of the TME in the context of disease recurrence and development of chemoresistance. We welcome submissions focused on the key cellular and molecular aspects of the HGSOC TME and their role in disease progression and clinical outcome.
Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mipi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI